U.S. Code · Título 21
Reporting on tobacco regulation activities
21 U.S.C. § 387v
Office of the Law Revision Counsel · release 119-142
Se muestra el texto operativo de la sección. Las notas estatutarias y el historial de enmiendas están en la fuente oficial.
In general
For fiscal year 2022 and each subsequent fiscal year for which fees are collected under section 387s of this title, the Secretary of Health and Human Services shall, not later than 180 days after the end of the fiscal year, prepare and submit to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate, an annual report that contains the information required under subsection (b).
Required information
Each report submitted under subsection (a) shall contain the following information for the previous fiscal year:
The amount obligated by the Center for Tobacco Products for each of the following activities:
The numbers of applications, categorized by class of tobacco product and review pathway under sections 387e, 387j, and 387k of this title, that were—
Public availability
The Secretary of Health and Human Services shall make the reports required under this section available to the public on the website of the Food and Drug Administration.
Limitations
Reporting under this section shall include best estimates for any reporting category for which the Food and Drug Administration does not have precise calculations. Such best estimates shall be accompanied with an explanatory statement for why the Food and Drug Administration does not have access to, or cannot calculate, the exact figure and a date by which the Food and Drug Administration will update its internal accounting procedures to allow for such reporting. If a category is successfully reported by the Food and Drug Administration with regard to another type of user fee but is provided a best estimate by the Center for Tobacco Products, the explanatory statement shall include information regarding how the Food and Drug Administration will align systems and apply learning across the agency to allow for accurate reporting.
(Pub. L. 117–103, div. P, title I, § 112, Mar. 15, 2022, 136 Stat. 790.)